Previous studies have shown that the synergistic activity and acceptable safety profile could be observed by the combination of checkpoint inhibitors and chemotherapy in the first‐line treatment of advanced NSCLC.28, 29 With the inclusion of two recent studies, our study drew consistent conclusion that compared with standard chemotherapy, the combination of chemotherapy and ICIs, regardless of atezolizumab or pembrolizumab could acquire significant benefits in mOS, OSR1y, mPFS, PFSR6m, PFSR1y, and ORR for PD‐L1 unselected patients in spite of higher incidence of grade ≥ 3 TRAEs. Here, CD274 is linked to non-small cell lung carcinoma.